menu
    • menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ ASTRAZENECA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","amount":"$390.0 million","upfrontCash":"$350.0 million","newsHeadline":"AstraZeneca divests rights to established hypertension medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Divestment","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.39000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.39000000000000001,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Atnahs Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS\u00ae (ravulizumab) in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza regulatory submission granted Priority Review in US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cediranib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease\r\n","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Trials Asthma Drug Alvesco To Fight COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Statement On SOLIRIS\u00ae (Eculizumab) And COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"$67.5 million","upfrontCash":"$52.5 million","newsHeadline":"AZ licences Movantik rights to RedHill","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.070000000000000007,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MAP2K1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Phase III ADAURA Trial will be Unblinded Early After Overwhelming Efficacy in the Adjuvant Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Circassia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Circassia To Terminate AstraZeneca Deal And Transfer Assets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol Powder","sponsorNew":"AstraZeneca \/ Circassia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Begins Efforts to Identify Antibodies Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Initiates CALAVI Clinical Trial With Calquence Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Preps Phase 3 Study of Ultomiris in Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaccitech and Oxford University Enter Partnership with AstraZeneca To develop and Distribute COVID-19 vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Vaccitech","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Lynparza shows further promise in prostate cancer study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Pits Fast-Rising Farxiga Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gastric-Cancer Drug Designated Breakthrough by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Regains Global Rights to Brazikumab From Allergan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$81.3 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Bevespi Aerosphere approved in China for patients with COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Tests Diabetes Drug Farxiga for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Plus Tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mina Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"saRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"$2,080.0 million","upfrontCash":"$60.0 million","newsHeadline":"Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Small interfering RNA","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":2.0800000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.0800000000000001,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Presents New Data Across Continuum of Care from its Broad Renal Portfolio at ERA-EDTA 2020 Virtual Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$930.0 million","upfrontCash":"$930.0 million","newsHeadline":"Alexion Completes Acquisition of Achillion","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0.93000000000000005,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.93000000000000005,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford\u2019s Potential New Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca ties up with Emergent BioSolutions to Make COVID-19 Vaccine in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"academia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advancing our Discovery of Novel Coronavirus-Neutralising Antibodies Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ academia","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ' Calquence Showed Promising Clinical Improvement in Majority of Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca to Showcase Leadership in Treating Type 2 Diabetes and Cardiorenal Complications at ADA 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dapagliflozin May Help Reduce Onset of Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cobra Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Health Ministry","pharmaFlowCategory":"D","amount":"$127.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil, AstraZeneca Sign $127 Million Deal To Produce Experimental COVID-19 Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"AstraZeneca \/ Brazilian Health Ministry","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breztri Aerosphere Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MAP2K1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion Completes Acquisition of Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breast Cancer Drug Capivasertib Enters Major Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Nod for Lynparza in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's BRILINTA Gets FDA Priority Review for the Reduction of Subsequent Stroke Acute Ischemic Stroke Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inozyme Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Inozyme Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ Unveils Detailed Data from THALES Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's FARXIGA Granted Fast Track Designation for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine AZD1222 Showed Robust Immune Responses in all Participants in Phase I\/II Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"SK Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"South Korea's SK Bioscience in Deal with AstraZeneca on Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion to Acquire Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca COPD Drug Finally Gets OK From FDA, inching closer to GSK leader","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India to Apply for Local Trials on Oxford's Vaccine by August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for the Treatment of Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Dumps ex-Achillion C3G Program After Seeing Phase 2 Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Reduced Respiratory Syncytial Virus Infections Requiring Medical Care in Healthy Premature Infants in Phase 2b Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":6,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6,"dosageForm":"","sponsorNew":"AstraZeneca \/ ASTRAZENECA","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Osimertinib Mesylate","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Government","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil's Bolsonaro Orders $360 million to Be Set Aside for AstraZeneca Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Brazilian Government","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Redx Pharma","pharmaFlowCategory":"D","amount":"$377.0 million","upfrontCash":"Undisclosed","newsHeadline":"Redx Signs Out Licensing Agreement With Astrazeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RXC006","moa":"Porcupine","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.38,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mexico Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca will Work with Mexico, Argentina on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Mexico Government","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Antengene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Therapeutic Goods Administration Approves First Phase I Trial of ATG-017 for Advanced Solid Tumors and Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATG-017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ\u2019s Fasenra Study Confirms Robust Efficacy in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Granted FDA Priority Review for Less-Frequent, Fixed-Dose Use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in Japan for the Treatment of Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for the Prevention and Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Phase III DAPA-CKD Trial Paradigm-Shifting Data to Be Presented at ESC 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Improves Survivalinn Kidney Disease Patients Study Shows","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Expands Development of Covid-19 Vaccine Azd1222 Into Us Phase III Clinical Trial Across All Adult Age Groups","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"$64.9 million","upfrontCash":"$19.4 million","newsHeadline":"Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Curia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in the EU for the Treatment of Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca to Begin Phase 1\/2 Clinical Trials of Coronavirus Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Neogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Neo-Antigen TCR Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Neo-Antigen T Cell Receptor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Neogene \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement on Astra Zeneca Oxford SARS-CO V-2 Vaccine, AZD1222, Covid-19 Vaccine Trials Temporary Pause","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India to Halt Trial of the Astrazeneca Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Fasenra Met Both Co-Primary Endpoints of Reduced Nasal Polyp Size and Blockage in the Ostro Phase III Trial","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Receives UK MHRA Approval to Resume Covid-19 Vaccine AZD1222 Clinical Trials in UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Research UK and AstraZeneca\u2019s New Antibody Maturation Technique Yields High-Affinity Arginase 2 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"C0021158","moa":"Arginase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Dogma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Acquires Dogma Therapeutics\u2019 PCSK9 Inhibitor Programme","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Government of Australia","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australia Secures Onshore Manufacturing Deal for Two Covid-19 Vaccines Developed By Oxford\/AstraZeneca and University of Queensland\/CSL","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":1.7,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.7,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Government of Australia","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Lynparza Recommended for Approval in the EU by CHMP for Brca-Mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Granted Breakthrough Therapy Designation in US for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canada joins countries in real-time AstraZeneca COVID vaccine review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Adds Israel Rights to Movantik\u00ae From AstraZeneca","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$486.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's COVID-19 Long-Acting AntiBody Combination AZD7442 Rapidly Advances into Phase III Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0.48999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Neogene","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Neogene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neogene \/ Neogene","highestDevelopmentStatusID":"2","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Targovax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces that the Oncos-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab-cwvz) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Pharma India will Launch Calquence in India on Oct 21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Forxiga Recommended for Approval in the EU by CHMP for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Tagrisso Granted Priority Review in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients with Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Enhertu Granted Priority Review in the US for the Treatment of HER2-Positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Forxiga Cardiovascular Outcomes Benefit Approved in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Advances Leadership in Renal Disease with More Than 80 Abstracts at ASN Kidney Week 2020 Reimagined","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innate Pharma","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50 M Payment from Astrazeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"NKG2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus\u2019s Novel Anti-TIGIT Antibody, Plus Imfinzi\u00ae in Stage III NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Bill & Melinda Gates Foundation and Open Philanthropy","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"IVX-411","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Icosavax \/ Bill & Melinda Gates Foundation and Open Philanthropy","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCLA Begins Recruitment For Phase 3 Of The Oxford University - AstraZeneca COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorises Restart of the Covid-19 AstraZeneca's Azd1222 Vaccine US Phase III Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza to Manufacture AstraZeneca's COVID-19 Long-Acting Antibody Combination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU (Fam-Trastuzumab Deruxtecan-NXKI) Granted Priority Review in the US For the Treatment of HER2-positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Om Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Om Pharma and Astrazeneca Enter Into Strategic Collaboration to Expand Presence in Respiratory and Immunology Fields in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Bacterial Lysates","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fusion Pharmaceuticals Collaborates with AstraZeneca to Develop and Commercialize Next-Gen Radiopharmaceuticals and Gene Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Radioactive labelled-antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU\u00ae Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Caelum Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved in the EU as 1st-line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in the EU for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brilinta Approved in the US to Reduce the Risk of Stroke in Patients with an Acute Ischaemic Stroke or High-Risk Transient Ischaemic Attack","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Aims to Bring Non-U.S. Vaccine Data Before the FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Calquence Approved in the EU for the Treatment of Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Provides Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising New Data for Ionis' Antisense Medicine Targeting PCSK9 Presented at American Heart Association Scientific Sessions 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ION449","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford University Breakthrough on Global COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's COVID-19 Vaccine Shows Midphase Efficay in Old Age People","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ National Institutes of Health","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Imfinzi approved in the US for less-frequent, fixed-dose use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Britain Starts Accelerated Review for AstraZeneca's Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ionis Announces third Investigational Antisense Medicine to treat Nonalcoholic Steatohepatitis (NASH) Enters Development","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ION455","moa":"PNPLA3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0.33000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ University of Oxford","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Reports Lokelma Label Update Approved in China for Patients with Hyperkalaemia on Chronic Haemodialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$320.0 million","newsHeadline":"AstraZeneca's Crestor to be Divested to Gr\u00fcnenthal in Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Divestment","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Gr\u00fcnenthal","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$39,000.0 million","upfrontCash":"$13,300.0 million","newsHeadline":"AstraZeneca To Acquire Alexion, Accelerating the Company's Strategic and Financial Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Acquisition","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":39,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":39,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca PLC","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ionis Announces Astra Zeneca's Initiation of Phase 2b Clinical Study of Its Antisense Medicine Targeting PCSK9 to Lower LDL-Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"AZD8233","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Demonstrates Growing Leadership in Breast Cancer at SABCS with Data From Its Innovative Medicines and Robust Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Camizestrant","moa":"Selective oestrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Calquence Data Across Four Trials Reinforces Cardiovascular Safety Profile in Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Halix BV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's AZD1222 Oxford Phase III Trials Interim Analysis Results Published in The LANCET","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Continues to Demonstrate Durable Responses with New Data from Destiny-Breast01 in HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Presents Results from First Combination Trial of ENHERTU\u00ae and Immune Checkpoint Inhibitor in Patients with HER2+ Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Recommended for Approval in the EU by CHMP for Less-Frequent, Fixed-Dose Use in Unresectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Roxadustat in Anaemia of Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in the Us for the Adjuvant Treatment of Patients with Early-Stage EGFR-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca gets DCGI Nod for Asthma Drug","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on SOURCE Phase III Trial for Tezepelumab in Patients with Severe, Oral Corticosteroid-Dependent Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Submitted Data for Vaccine Approval, UK's Hancock Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (Olaparib) Receives Three New Approvals in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update On Rolling Review of Astra Zeneca\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s COVID-19 Vaccine Authorised for Emergency Supply in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trixeo Aerosphere Approved in the EU for Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Begins Program to Assess Covid-19 Vaccines Combinations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Gamaleya Research Institute of Epidemiology and Microbiology","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCLH Doses First Patient in the World in Covid-19 Antibody Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Provides Update on Phase 3 Study of ULTOMIRIS\u00ae (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Serum Institute Expects WHO Emergency Approval for AstraZeneca Shot Soon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in the EU for Less-Frequent, Fixed-Dose Use in Unresectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BenevolentAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Care Access Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Care Access Research Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Positive Gastric Adenocarcinomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"R-Pharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azerbaijan issues Permit to Conduct World\u2019s First Clinical Trials of Vaccine Combination, Sputnik V and COVID-19 Vaccine AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Calquence Met Primary Efficacy Endpoint in Head-To Head Trial Against Ibrutinib in Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Symbicort Turbuhaler approved in China as an Anti-Inflammatory Reliever in Mild Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Applies for COVID-19 Vaccine's Regulatory Approval in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan and ENHERTU\u00ae Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Enters into Outsourcing Agreement to Manufacture AstraZeneca COVID-19 Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes Deal with AstraZeneca for European Rights to CRESTOR\u2122 (Rosuvastatin)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Agreement","leadProduct":"Rosuvastatin","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.34999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Gr\u00fcnenthal","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine AstraZeneca Confirms 100% Protection Against Severe Disease, Hospitalisation and Death","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford Coronavirus Vaccine Shows Sustained Protection of 76% During the 3-month Interval Until the Second Dose","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Heart Failure Drug Forxiga Now Approved in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Provides Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab as 1st-line treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Licensing Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alexion Pharmaceuticals \/ Arcturus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGA Provisionally Approves AstraZeneca's COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo and AstraZeneca ENHERTU\u00ae Authorised in the UK for the Treatment of Her2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IDMC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDMC Concludes that OlympiA Trial of Lynparza Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford\/AstraZeneca COVID Shot Less Effective Against South African Variant: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exclusive: U.S. Green Light for AstraZeneca Vaccine Could Come in April, Independent Monitors Assessing Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Lung02 Phase 2 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV\/hMPV Vaccine Candidate Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Series B Financing","leadProduct":"Stabilized prefusion F antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Reports, DESTINY-CRC02 Phase 2 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Saint Luke's Health System","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Provides Update on the DARE-19 Phase III trial for Farxiga in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Saint Luke's Health System","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Accelerates Early Oncology Pipeline Across Key Strategic Scientific Platforms at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AZD5305","moa":"PARP1 selective","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in China for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Accepted for Use Within NHS Scotland for Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Approved C5 Complement Inhibitor Recommended by NICE for NHS Use","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Pharma launches Benralizumab (Fasenra) for asthma patients; Stock skyrockets 11%","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selumetinib Gets EU Recommendation as the First Medicine for Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MEK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Recommended for Approval in the EU by CHMP For the Adjuvant Treatment of Patients with Early-Stage Egfr-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Drops BCMA Drug After Seeing Early Clinical Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MEDI2228","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxford-AstraZeneca Paediatric Vaccine Trial Halted Amid Blood Clot Concerns","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alchemab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alchemab to Collaborate with AstraZeneca on Prostate Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI and Tremelimumab With Chemotherapy Shows Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Medicines Regulator Issues its First Authorisation Under Project Orbis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Results in Patients with Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, AstraZeneca Strengthen Case for Approval of Tezepelumab in Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Upgrades Financial Guidance for Supply Agreement With AstraZeneca for Manufacture of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Abbott Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma Acquires Rights to Trademarks of Three Diabetes Drug Brands in India from AstraZeneca","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in the EU for the Adjuvant Treatment of Patients with Early-Stage Egfr-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Proteros","pharmaFlowCategory":"D","amount":"$73.3 million","upfrontCash":"Undisclosed","newsHeadline":"Proteros to Receive Research Funding AND Milestone Payments Plus Royalties","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anifrolumab Showed Early and Sustained Treatment Benefit for Patients with Systemic Lupus Erythematosus in the TULIP Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Showed Fewer Incidences of Atrial Fibrillation versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Caelum Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Nipro Glass","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca, Nipro Sign COVID-19 Vaccine Deal for Supply in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2021","year":"2021","type":"Agreement","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU\u00ae Initiated in Patients with HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase III Pivotal Trial of once wEekly Exenatide in Adolescents Aged 10\u201317 Shows Benefit for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hutchmed Announces Savolitinib Approved in China for Patients with Lung Cancer with Met Exon 14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ HUTCHMED","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"F-star Therapeutics","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$12.0 million","newsHeadline":"F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.31,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Announces First Commercial Sale of ORPATHYS\u00ae in China, Triggering a US$25 million Milestone Payment from AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Collaboration","leadProduct":"Savolitinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Suvratoxumab","moa":"Staphylococcus aureus alpha toxin binding","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intradermal Injection","sponsorNew":"AstraZeneca \/ Aridis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$39,000.0 million","upfrontCash":"$13,300.0 million","newsHeadline":"Acquisition of Alexion Completed","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Acquisition","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":39,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":39,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BYDUREON BCise Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA\u2019s CRDA Committee Votes Against Approval Of AstraZeneca\u2019s Roxadustat to Treat Anaemia in Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab MEDLEY Phase II\/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezepelumab Granted Priority Review By U.S. FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Momelotinib","moa":"JAK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Sierra Oncology","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo\u2122) for Systemic Lupus Erythematosus (SLE)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab-fnia","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Improved Progression-Free Survival in DESTINY-Breast03 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo Company","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Seeks More Trial Data on Astrazeneca\u2019s NDA for Roxadustat for CKD","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS\u00ae in Patients with MET Amplified Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Combination Between AstraZeneca and The First Component of Sputnik V Vaccine (Sputnik Light) Demonstrates High Immunogenicity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca PROVENT Phase III Pre-Exposure Prophylaxis Trial Of AZD7442 to Treat Covid-19 Meets Primary Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Phase III FoCus Trial of ALXN1840 to Treat Wilson Disease Meets Primary Endpoints Showing Improvement in Copper Mobilisation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on CHAMPION-ALS Phase III trial of Ultomiris in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Shenzhen Kangtai Biological Products","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recombinant Covid-19 Vaccine (Adenovirus Vector) Licensed for Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"AZD1222","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension for Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS\u00ae and TAGRISSO\u00ae Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fixed-Dose Combination of Albuterol and Budesonide Showed benefits for Asthma Patients in MANDALA and DENALI Phase III Trials","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Avillion","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Ultomiris Approved for Use on Children in EU","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Caelum Biosciences","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astra Zeneca to Fully Acquire Caelum Biosciences","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.5,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.5,"dosageForm":"Sterile Solution","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monalizumab Data from COAST Trial Presented at ESMO Congress 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Monalizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca and Sputnik Light Covid Vaccines Show Antibody Growth in Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Caelum Biosciences","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$150.0 million","newsHeadline":"Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.5,"dosageForm":"Sterile Solution","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$143.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinCor Pharma Raises $143 Million in Series B Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series B Financing","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ General Atlantic","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Tremelimumab Significantly Improved Overall Survival In HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Granted Breakthrough Therapy Designation in US For Patients With HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of Evusheld (Tixagevimab and Cilgavimab)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"5","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approval Of Mixing and Matching of COVID Booster Shots By FDA is yet Another Confirmation of Efficacy of Vaccine Cocktail Approach Pioneered by The Russian Sputnik V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca to Transfer Global Rights For Eklira and Duaklir to Covis Pharma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.27000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.27000000000000002,"dosageForm":"Inhalation Powder","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Integral Molecular","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"AstraZeneca \/ Integral Molecular","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Tempus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tempus Signs Strategic Collaboration Agreement With AstraZeneca to Advance Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD8601 EPICCURE Phase II Trial Demonstrated Safety and Tolerability in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"AZD8601","moa":"VEGF A expression","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Epicardial Injection","sponsorNew":"AstraZeneca \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LOKELMA\u00ae Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS\u00ae and TAGRISSO\u00ae Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (Olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA\u00ae (Olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Termination","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BenevolentAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca\u2019s Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 with New Data Underscoring Ambition to Redefine Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld (Formerly AZD7442) Long-Acting Antibody Combination Authorised for Emergency Use in the US for Pre-Exposure Prophylaxis (Prevention) of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Additional Analyses Further Reinforce Ground-Breaking Efficacy in Patients with HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$3,585.0 million","upfrontCash":"$200.0 million","newsHeadline":"AstraZeneca and Ionis Sign Deal to Develop and Commercialise Eplontersen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":3.5899999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.5899999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$3,585.0 million","upfrontCash":"$200.0 million","newsHeadline":"Ionis and AstraZeneca Close Deal to Develop and Commercialize Eplontersen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AstraZeneca","amount2":3.5899999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.5899999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-Acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Independent FDA Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TEZSPIRE (Tezepelumab) Approved in the US for Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saphnelo Recommended for Approval in The EU by CHMP for The Treatment of Patients with Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-Acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Studies from Oxford and Washington Universities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Regulatory Submission Accepted Under FDA Priority Review in The US for Adults with Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and AstraZeneca Expand Strategic Manufacturing Partnership to Include COVID-19 and Cancer Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Partnership","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.38,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.38,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.27000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.27000000000000002,"dosageForm":"Inhalation Powder","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Scorpion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$75.0 million","newsHeadline":"AstraZeneca and Scorpion Therapeutics Enter Agreement to Discover, Develop and Commercialise Novel Cancer Treatments Against \u2018Undruggable\u2019 Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$193.6 million","upfrontCash":"Undisclosed","newsHeadline":"CinCor Pharma Announces Pricing of Initial Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Public Offering","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.19,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI\u00ae (durvalumab) and LYNPARZA\u00ae (olaparib) Data at ASCO GI and GU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","amount":"$215.5 million","upfrontCash":"$12.5 million","newsHeadline":"Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"OV350","moa":"KCC2 transporter","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.22,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"AstraZeneca \/ Ovid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-care in 1st-line Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire\u2122 (tezepelumab-Ekko) Now Available in The United States for The Treatment of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab EMA Regulatory Submission Accepted Under Accelerated Assessment for RSV Protection in All Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saphnelo Approved in The EU for The Treatment of Moderate to Severe Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Anifrolumab-fnia","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Reduced Risk of Death By 20% in 1st-Line Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Vaxzevria Data Further Support Its Use as Third Dose Booster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients With HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Honeywell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Honeywell Teams With AstraZeneca To Develop Next-Generation Respiratory Inhalers That Use Near-Zero Global Warming Potential Propellant","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pressurised Metered-dose Inhaler","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Neurimmune","pharmaFlowCategory":"D","amount":"$760.0 million","upfrontCash":"$30.0 million","newsHeadline":"AstraZeneca and Neurimmune Close Exclusive Global Collaboration and Licence Agreement to Develop and Commercialise NI006","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin amyloid","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0.76000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"HUTCHMED Receives a US$15 Million Milestone From AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS\u00ae in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Savolitinib","moa":"c-MET receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Significantly Protected Infants Against RSV Disease in Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Significantly Protected Infants Against RSV Disease in Phase III MELODY Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved in the US as Adjuvant Treatment for Patients With Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Fasenra in Chronic Rhinosinusitis with Nasal Polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves LYNPARZA\u00ae (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVUSHELD\u2122 Long-acting Antibody Combination Retains Neutralizing Activity Against Omicron Variants Including Ba.2 in New Independent Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Washington University School","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca\u2019s Antibody Combination, Evusheld (Tixagevimab Co-packaged With Cilgavimab) Authorised for Use in Great Britain for Pre-exposure Prophylaxis (Prevention) of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients With Germline Brca-mutated High-risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2- Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on CALLA Phase III trial Of Concurrent Use of Imfinzi and Chemoradiotherapy in Locally Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ondexxya Approved in Japan for Reversal of Acute Major Bleeds in Patients on Factor Xa Inhibitors","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Andexanet Alfa","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-acting Antibody Combination Approved in the EU for Pre-exposure Prophylaxis (Prevention) of COVID-19 in a Broad Population","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Pre-exposure Prophylaxis (Prevention) of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$25.0 million","newsHeadline":"Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"HBM7022","moa":"CLDN18.2\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Demonstrated Sustained Improvements in Functional Activities and Quality of Life in Adults With Generalised Myasthenia Gravis Through 60 Weeks","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZD8233 Reduced Low-density Lipoprotein Cholesterol Levels by 73% in Patients With High-risk Hypercholesterolemia in ETESIAN Phase IIb Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Antisense Oligonucleotide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Reaction Biology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Adavosertib","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Reaction Biology","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVUSHELD\u2122 Significantly Protected Against Symptomatic COVID-19 for At Least Six Months in PROVENT Phase III trial in High-Risk Populations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Significantly Protected Against Symptomatic COVID-19 For at Least Six Months in PROVENT Phase III Trial in High-Risk Populations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innate Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"$250.0 million","newsHeadline":"Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Agreement","leadProduct":"Monalizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tremelimumab Accepted Under Priority Review in the US for Patients With Unresectable Liver Cancer in Combination With Imfinzi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Tremelimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"CT5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in The US for Adults with Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Granted Breakthrough Therapy Designation in The US for Patients with HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults With Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in the US for Patients With HER2-positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Met Primary Endpoint in DELIVER Phase III trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients With Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anifrolumab Showed Early and Sustained Treatment Benefit for Patients With Systemic Lupus Erythematosus in the TULIP Clinical Trial Programme And Planing to Conduct Phase III Study for Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"Type I IFN receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Juvise Pharmaceuticals Successfully Syndicated Its EUR 213 Million Financing in Less than One Month","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Anastrozole","moa":"Aromatase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Baili Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 Bispecific Antibody, in Combination with Tagrisso\u00ae in Patients with Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Osimertinib Mesylate","moa":"EGFR \/ HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Neogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"NT-125","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neogene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LifeArc Co-Founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Licensing Agreement","leadProduct":"SARS-CoV-2 Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BenevolentAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Achieves Third Milestone in Its AI-enabled Drug Discovery Collaboration With AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Aims to Transform Cancer Care with Practice-Changing Data at ASCO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Anifrolumab","moa":"IFN\/IFNAR complex","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts New Drug Application Filed by Avillion for Astra Zeneca's PT027 For the As-Needed Treatment or Prevention of Symptoms in Asthma Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxzevria Approved in the EU as Third Dose Booster Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innate Pharma","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"$50.0 million","newsHeadline":"Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"IPH5201","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Demonstrates Pipeline and Portfolio Strength Across Malignant and Rare Haematological Diseases at EHA 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukaemia With 90% of Patients Surviving Five Years in Elevate-tn Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eplontersen Met Co-primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III trial For Hereditary Transthyretin-mediated Amyloid Polyneuropathy (ATTRv-PN)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Eplontersen","moa":"ATTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Biocartis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Phase 3 PROpel Trial of LYNPARZA\u00ae (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Recommended for Approval in the EU by CHMP for Patients with HER2-Positive Metastatic Breast Cancer Treated with a Prior anti-HER2-based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"WTX101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 1\/1b Results for VLP Vaccine Candidate IVX-121 Against RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Significantly Improved Pathologic Complete Response in Aegean Phase III Trial in Resectable Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients With Germline BRCA-mutated Her2-Negative High-risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilisation From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Tiomolibdate Choline","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs New Three Year Agreement with AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2022","year":"2022","type":"Agreement","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI\u00ae (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO at the 2022 WCLC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Reduced the Risk of Disease Progression or Death by 50% Vs. Chemotherapy in Patients With HER2-low Metastatic Breast Cancer With HR-positive and HR-negative Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior AntiHER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Recommended for Approval in The EU by CHMP For the Treatment of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-411","moa":"SARS-CoV-2 virus protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Recommended for Approval in the EU by CHMP for the Treatment of Adults with Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Thorne HealthTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Thorne HealthTech Announces Two-Year Collaboration with AstraZeneca on Disease Discovery System to Advance Novel Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Monalizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence\u00ae (Acalabrutinib) Tablet Formulation Approved in the US Across Current Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in the US as the First HER2-Directed Therapy for Patients With HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"Undisclosed","newsHeadline":"CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Public Offering","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0.23000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,265.0 million","upfrontCash":"$100.0 million","newsHeadline":"Astra Zeneca Completes Acquisition of TeneoTwo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD19\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":1.27,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.27,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUTCHMED and AstraZeneca Announce that TAGRISSO\u00ae Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and\/or Amplification in SAVANNAH Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Approved in the US as the First HER2-directed Therapy for Patients With Previously Treated HER2-mutant Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Significantly Delayed Disease Progression in DESTINY-breast02 Phase Iii Trial Vs. Physician\u2019s Choice of Treatment in Patients With HER2-positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Hutchmed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients With High Levels of MET Overexpression and\/or Amplification in SAVANNAH Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Significantly Delayed Disease Progression in DESTINYBreast02 Phase 3 Trial Versus Physician\u2019s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Aims to Transform Cancer Outcomes With New Data Across Industry-leading Portfolio at ESMO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-Acting Antibody Combination Approved for Prevention and Treatment of Covid-19 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show Farxiga Significantly Lowers the Risk of Cardiovascular Death in Patients With Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients With Mildly Reduced or Preserved Ejection Fraction in Deliver Phase III Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in Japan for the Treatment of Adults With Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Approved in Japan for the Adjuvant Treatment of Patients With Early-stage EGFR-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved in Japan as Adjuvant Treatment for Patients With BRCA-mutated HER2-Negative High-risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in China for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients With Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Gatehouse Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Partnership","leadProduct":"GHB-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Demonstrated 5.5-year Median Disease-free Survival in the Adjuvant Treatment of Patients With EGFR-mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) Plus Chemotherapy Further Improved Overall Survival Benefit in Advanced Biliary Tract Cancer in The TOPAZ-1 Phase III Trial, Reducing the Risk of Death by 24% in Additional Follow-Up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Further Improved Overall Survival Benefit in Advanced Biliary Tract Cancer in the TOPAZ-1 Phase III trial, Reducing the Risk of Death by 24% in Additional Follow-up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and Tremelimumab With Chemotherapy Demonstrated Sustained Survival Benefit in Metastatic Non-small Cell Lung Cancer, Nearly Doubling the Number of Patients Alive After Three Years Vs. Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Continues to Demonstrate Clinically Meaningful Tumour Response in Patients With HER2-Mutant Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza in Combination With Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-line Advanced Ovarian Cancer Across Two Phase III Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Beyfortus\u00ae (Nirsevimab) For Prevention of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Approved In China As 1st-line Maintenance Treatment With Bevacizumab For HRD-positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Approved In The Eu For The Treatment Of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus (nirsevimab) Recommended for Approval in the EU by CHMP for the Prevention of RSV Lower Respiratory Tract Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danicopan (ALXN2040) Add-On to Ultomiris or Soliris Met Primary Endpoint In Alpha Phase III Trial For Patients With Paroxysmal Nocturnal Haemoglobinuria Who Experience Clinically Significant Extravascular Haemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danicopan (ALXN2040) Add-On to ULTOMIRIS\u00ae (ravulizumab-cwvz) or SOLIRIS\u00ae (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evusheld Long-acting Antibody Combination Recommended for Approval in the EU For the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in Europe for the Treatment of Adults With Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Approved in Japan for the Treatment of Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Tezepelumab","moa":"TSLP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Koselugo Approved in Japan for Paediatric Patients With Plexiform Neurofibromas in Neurofibromatosis Type 1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MEK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"LogicBio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alexion, AstraZeneca Rare Disease to Acquire LogicBio\u00ae Therapeutics to Accelerate Growth in Genomic Medicine","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives FDA Approval For First Companion Diagnostic To Identify Patients With HER2 Low Metastatic Breast Cancer Eligible For ENHERTU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Illumina","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Aims To Advance NMOSD Treatment Landscape With Exceptional ULTOMIRIS\u00ae (ravulizumab-cwvz) Efficacy Data at ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Aims To Advance NMOSD Treatment Landscape With Exceptional ULTOMIRIS (ravulizumab-cwvz) Efficacy Data At ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDWeek Data Reinforces AstraZeneca\u2019s Commitment To Advance Science In Vaccines And Immune Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Aims To Advance NMOSD Treatment Landscape With Exceptional Ultomiris Efficacy Data At ECTRIMS 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat at the Upcoming 29th International Society of Hypertension 2022 Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imjudo (tremelimumab) in Combination with Imfinzi Approved in the US for Patients With Unresectable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Tremelimumab","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Nephrology Kidney Week 2022","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on the MESSINA Phase III Trial for Fasenra in Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capivasertib Plus Faslodex Significantly Improved Progression-free Survival Vs. Faslodex In CAPItello-291 Phase III Trial In Advanced HR-positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Capivasertib","moa":"AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX\u00ae (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Camizestrant","moa":"SERD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Showed Zero Relapses In Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) With Median Treatment Duration Of 73 Weeks","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"C5 complement","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants First Approval Worldwide Of Beyfortus\u00ae (Nirsevimab) For Prevention Of RSV Disease In Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus Approved In The EU For The Prevention Of RSV Lower Respiratory Tract Disease In Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Grants First Approval Worldwide Of Beyfortus\u00ae (nirsevimab) For Prevention Of RSV Disease In Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Aerosol","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and Imjudo With Chemotherapy Approved in the US for Patients With Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Expands Global Footprint In Rare Disease With Availability Of First Alexion Rare Disease Therapy For Patients In China","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Improved Symptom Burden And Health-related Quality Of Life In Patients With Mildly Reduced Or Preserved Ejection Fraction In DELIVER Phase III Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"LogicBio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio\u00ae Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Compugen","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1\/TIGIT Bispecific","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"AZD2936","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Recommended for Approval in the EU by CHMP For Patients With Previously Treated HER2-positive Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Recommended for Approval in the EU by CHMP as First Immunotherapy Regimen for Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza in Combination With Abiraterone Recommended for Approval in the EU by CHMP As 1st-line Treatment for Patients With Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Neogene","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$200.0 million","newsHeadline":"AstraZeneca To Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"TCR Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"C4X Discovery","pharmaFlowCategory":"D","amount":"$402.0 million","upfrontCash":"$2.0 million","newsHeadline":"C4XD Agreement with AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Agreement","leadProduct":"C4X_6665","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.40000000000000002,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capivasertib Plus Faslodex Reduced the Risk of Disease Progression or Death by 40% Versus Faslodex in Advanced HR-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camizestrant Significantly Delayed Disease Progression in Advanced Er-Positive Breast Cancer, Adding at Least 3.5 Months Benefit versus Faslodex","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Camizestrant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Supplemental New Drug Application Submitted in Japan for Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on PEARL Phase III Trial of Imfinzi Monotherapy In Stage IV Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy Approved In The EU As First Immunotherapy Regimen For Patients With Advanced Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Approved in Japan for Adults with Treatment-Na\u00efve Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Imjudo Approved in Japan for Advanced Liver and Non-Small Cell Lung Cancers, and Imfinzi Approved for Unresectable Biliary Tract and Liver Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza in Combination with Abiraterone Approved in The EU as 1st-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Recommended for Approval in The EU by CHMP For Patients With HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Imjudo Recommended for Approval in The EU by CHMP For the Treatment of Advanced Liver and Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Recommended for Approval in The EU by CHMP for Symptomatic Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Priority Review of Lynparza in Combination with Abiraterone in Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab US Regulatory Submission Accepted For The Prevention Of RSV Lower Respiratory Tract Disease In Infants And Children Up To Age 24 Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Nirsevimab Application As First Protective Option Against RSV Disease For All Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"CinCor Pharma","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,300.0 million","newsHeadline":"AstraZeneca to Acquire Cin Cor Pharma to Strengthen Cardiorenal Pipeline","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":1.8,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airsupra (PT027) Approved in the US for Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Avillion LLP","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tezspire Approved for Self-Administration in The EU In a New Pre-Filled Pen","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Tezepelumab-ekko","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Neogene","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$320.0 million","newsHeadline":"Acquisition of Neogene Therapeutics Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0.32000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Food and Drug Administration Emergency Use Authorisation of Evusheld","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Neurimmune","pharmaFlowCategory":"D","amount":"$760.0 million","upfrontCash":"$30.0 million","newsHeadline":"AstraZeneca and Neurimmune Sign Exclusive Global Collaboration and Licence Agreement to Develop and Commercialise NI006","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin amyloid","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0.76000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,265.0 million","upfrontCash":"$100.0 million","newsHeadline":"AstraZeneca to Acquire TeneoTwo and Its Clinical-Stage T-Cell Engager, Strengthening Haematological Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD19\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":1.27,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.27,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in The EU For the Treatment of Symptomatic Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Rilvegostomig","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Gets CDSCO Nod for Drug to Treat Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence tablet Formulation Approved in The EU for Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"CinCor Pharma","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"$1,300.0 million","newsHeadline":"Acquisition of CinCor Pharma Complete","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Acquisition","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":1.8,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,163.0 million","upfrontCash":"$63.0 million","newsHeadline":"Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":1.1599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Imjudo Approved in The EU for Patients with Advanced Liver and Non-Small Cell Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Granted FDA Fast Track Designation for IVX-A12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in China for Patients With HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan-nxki","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Lynparza in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumor Types in DESTINYPanTumor02 Phase 2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Significantly Improved Event-Free Survival In AEGEAN Phase III Trial for Patients with Resectable Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Demonstrated Strong Overall Survival Benefit in The ADAURA Phase III Trial for Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Approves Prostate Cancer Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Granted First Regulatory Approval in China for Adults with Previously Treated Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aridis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"$11.0 million","newsHeadline":"AstraZeneca Pulls Pneumonia Collab With Aridis Over Allegations Of A Missed Payment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Termination","leadProduct":"Suvratoxumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"AstraZeneca \/ MedImmune","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$1,163.0 million","upfrontCash":"$63.0 million","newsHeadline":"License Agreement with KYM Biosciences for CMG901, a Claudin-18.2 Antibody Drug Conjugate, Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":1.1599999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1599999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Reports Positive Topline 66-Week Results of Eplontersen Phase 3 Study for Patients With ATTRv-PN","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Recommended for Approval in The EU By CHMP For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eplontersen Demonstrated Sustained Benefit in Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) Through 66 Weeks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain Cargo\u24c7 for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae and IMFINZI\u00ae Combination Improved Progression-Free Survival in Newly Diagnosed Patients with Advanced Ovarian Cancer without Tumor BRCA Mutations In DUO-O Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.0 million","newsHeadline":"Sobi to Streamline Nirsevimab Contractual Arrangements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Termination","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$674.9 million","upfrontCash":"$131.7 million","newsHeadline":"Nirsevimab: Sanofi, AstraZeneca and Sobi Simplify Contractual Agreements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Agreement","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.67000000000000004,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi-Based Treatment Before and After Surgery Reduced the Risk of Disease Recurrence, Progression Events or Death by 32% in Resectable Non-Small Cell Lung Cancer in The AEGEAN Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves BEYFORTUS\u2122 (nirsevimab) For the Prevention Of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on FDA Advisory Committee Vote on LYNPARZA\u00ae (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sernova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Receives Approval in India to Import and Market Trastuzumab Deruxtecan for The Treatment of Select HER-2 Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"$4,080.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"siRNA Therapeutic","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":4.0800000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":4.0800000000000001,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Transgene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Scraps Transgene Pact in Blow to Oncolytic Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060\/AZD1402)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Elarekibep","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Koselugo Approved in China for Paediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Selumetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck & Co. Inc.","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Extended in The US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to A Broader Range of Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in The EU for Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$55.0 million","newsHeadline":"LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Delivers 83% Reduction in RSV Infant Hospitalizations in A Real-World Clinical Trial Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"F-star Therapeutics","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$12.0 million","newsHeadline":"F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Chemotherapy Demonstrated Strong Improvement in Progression-Free Survival for Patients with EGFR-Mutated Advanced Lung Cancer in FLAURA2 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) Plus LYNPARZA\u00ae (olaparib) and IMFINZI Alone Both Significantly Improved Progression-free Survival in Advanced Endometrial Cancer When Added to Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultomiris Approved in Japan for the Prevention of Relapses in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza plus Abiraterone Approved in the US for the Treatment of BRCA-mutated Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Brazikumab Development Programme","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Brazikumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AbbVie Inc","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Andexanet Alfa","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Quell Therapeutics","pharmaFlowCategory":"D","amount":"$2,085.0 million","upfrontCash":"$85.0 million","newsHeadline":"Astra Zeneca Announces Agreement with Quell Therapeutics to Develop, Manufacture and Commercialise Engineered T-Regulatory Cell Therapies for Autoimmune Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Treg-based Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":2.0899999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.0899999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Unanimously Recommended by FDA Advisory Committee for the Prevention of RSV Lower Respiratory Tract Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danicopan as Add-on to Ultomiris or Soliris Improved Haemoglobin Levels and Maintained Disease Control in Patients with PNH Experiencing Signs or Symptoms of Clinically Significant Extravascular Haemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capivasertib In Combination With Faslodex (Fulvestrant) Granted Priority Review In The Us For Patients With Advanced Hr-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved In China For The Treatment Of Adults With Refractory Generalised Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cholesgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cholesgen to Enter into a Drug Discovery Collaboration and Licensing Option Agreement in Hypercholesterolemia with AstraZeneca","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060\/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Elarekibep","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Recommended for Approval in the EU by CHMP for Children and Adolescents with Refractory Generalised Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer in Tropion-Lung01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xigduo XR Approved in China for Adults with Type-2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Agreement","leadProduct":"BBP-398","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Beyfortus (nirsevimab-alip) to Protect Infants Against RSV Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AG10 (Acoramidis) is an Investigational, Orally-Administered Small Molecule Designed to Potently Stabilize Tetrameric Transthyretin (TTR)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Lynparza in Combination with Abiraterone and Prednisone or Prednisolone for Patients with BRCA Mutated Metastatic Castration-resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion, AstraZeneca Rare Disease, Enters Agreement with Pfizer to Acquire a Portfolio of Preclinical Rare Disease Gene Therapies","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Alexion Pharmaceuticals","amount2":1,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved in the EU for Children and Adolescents with Refractory Generalised Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Demonstrated Clinically Meaningful Progression-free Survival and Overall Survival Across Multiple HER2-expressing Advanced Solid Tumours in DESTINY-PanTumor02 Phase II trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$3,800.0 million","upfrontCash":"$200.0 million","newsHeadline":"Ionis Expands Eplontersen Agreement with AstraZeneca to Include Exclusive Rights in Latin America","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Eplontersen","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":3.7999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":3.7999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"LianBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"BBP-398","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Astrazeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Approved in China to Reduce the Risk of Cardiovascular Death And Hospitalisation in Adult Patients With Symptomatic Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza Plus Abiraterone Approved in Japan for the Treatment of BRCA-mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Olaparib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved in Japan for Paediatric Patients with Generalised Myasthenia Gravis (gMG)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Approved in China for Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on US Regulatory Review of Ultomiris in NMOSD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Verge Genomics","pharmaFlowCategory":"D","amount":"$882.0 million","upfrontCash":"$42.0 million","newsHeadline":"Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alexion Pharmaceuticals","amount2":0.88,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FASENRA Met the Primary Endpoint in the MANDARA Phase III Trial in Eosinophilic Granulomatosis with Polyangiitis (EGPA)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Benralizumab","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion Completes Purchase and Licence Agreement for Early-Stage Rare Disease Gene Therapy Portfolio from Pfizer","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Gene Therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Alexion Pharmaceuticals","amount2":1,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients With HR-Positive, HER2-Low or Negative Breast Cancer in Tropion-Breast01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BioCity Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a Monoclonal Antibody Targeting Anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Collaboration","leadProduct":"BC3402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forxiga Met Primary Endpoint in T2NOW Phase III trial, One of the Largest Paediatric Type 2 Diabetes Studies Performed to Date","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Na\u00efve Patients with First-Line CLL\/SLL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-mutated Advanced Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soliris Approved in China for the Ttreatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Eccogene","pharmaFlowCategory":"D","amount":"$2,010.0 million","upfrontCash":"$185.0 million","newsHeadline":"Eccogene Enters Exclusive License Agreement with AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AstraZeneca","amount2":2.0099999999999998,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"$945.0 million","upfrontCash":"$105.0 million","newsHeadline":"Astrazeneca Announces Collaboration and Investment Agreement with Cellectis to Accelerate Cell Therapy and Genomic Medicine Ambitions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0.94999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"$5.0 million","newsHeadline":"Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.28000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Yousen Jianheng Biopharmaceutical","pharmaFlowCategory":"D","amount":"$419.0 million","upfrontCash":"$24.0 million","newsHeadline":"Uson Health Announces an Exclusive Global Licensing Agreement with AstraZeneca for UA022, a New Small Molecule Drug Candidate Targeting the KRAS G12D Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"UA022","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration Accepts for Review AstraZeneca\u2019s Supplemental Biologics License Application for Self-administration of FLUMIST\u00ae QUADRIVALENT (Influenza Vaccine Live, Intranasal)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Live Intranasal Influenza Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"$5.0 million","newsHeadline":"Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration \n- AstraZeneca's Truqap\u2122 for the treatment of metastatic breast cancer approved in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.28000000000000003,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) plus Bevacizumab Met Primary Endpoint for Progression-Free Survival in Liver Cancer Eligible for Embolization in EMERALD-1 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Icosavax","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"IVX-A12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AbSci","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Allorion Therapeutics","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$40.0 million","newsHeadline":"Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.54000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Gracell Biotechnologies to be Acquired by AstraZeneca, Furthering Cell Therapy Ambition Across Oncology and Autoimmune Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":1.2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Compugen","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Omniose","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Omniose Announces Scientific Collaboration With AstraZeneca to Research Vaccines for Serious Bacterial Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Turbine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Compugen","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus Approved in China for The Prevention of Rsv Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Nirsevimab-alip","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces Open Enrollment for Phase 1b\/2 Study Evaluating Ampligen\u00ae (rintatolimod) in Combination with AstraZeneca's Imfinzi\u00ae (durvalumab) for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIRSUPRA\u00ae (albuterol\/budesonide) Now Available as The First and Only FDA-Approved Anti-Inflammatory Rescue Option for Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Salbutamol Sulphate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Granted Priority Review in The US for Patients with Metastatic HER2-positive Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Transarterial Chemoembolisation (TACE) and Bevacizumab Reduced the Risk of Disease Progression or Death by 23% vs. TACE in Liver Cancer Eligible for Embolisation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b\/2 Study Evaluating Ampligen\u00ae (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Demonstrated Overwhelming Efficacy Benefit for Patients with Unresectable, Stage III EGFR-Mutated Lung Cancer In LAURA Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Icosavax","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Acquisition of Icosavax Completed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"IVX-A12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Gracell Biotechnologies Acquisition Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Acquisition","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":1.2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.2,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voydeya Recommended for Approval in the EU by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with Pnh Who Have Residual Haemolytic Anaemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Kura Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"AstraZeneca to Acquire Fusion to Accelerate the Development of Next-generation Radioconjugates to Treat Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":2.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":2.3999999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo\u00ae Technology for Neurodegenerative Disease in Research Collaboration with Alexion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab-cwvz) Approved in the US for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beyfortus Approved in Japan for the Prevention of RSV Disease in Infants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso with the Addition of Chemotherapy Showed Favourable Trend in Overall Survival in EGFR-mutated Advanced Lung Cancer with Further Follow Up in FLAURA2 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza and Imfinzi Demonstrated Strong Clinical Benefit and More than Doubled Median Duration of Response vs. Chemotherapy in Patients with Mismatch Repair Proficient Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA, AKT1 or PTEN Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Truqap Plus Faslodex Approved in Japan for Patients with Advanced HR-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Silence Therapeutics","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$80.0 million","newsHeadline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"mRNAi-based Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0.56999999999999995,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma Enters Exclusive Pact to Distribute Astrazeneca's Anti-Asthma Drug Symbicort in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Budesonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"AstraZeneca \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","amount":"$1,050.0 million","upfrontCash":"$800.0 million","newsHeadline":"Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"AstraZeneca","amount2":1.05,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":1.05,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRUQAP\u2122 (capivasertib) Plus Fulvestrant Approved in The Us for Patients with Advanced HR-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-term ALPHA Phase III Trial Data Showed Danicopan as Add-on to Ultomiris or Soliris Sustained Clinical Improvements in Subset of Patients with Pnh Experiencing Clinically Significant Extravascular Haemolysis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on CRYSTALIZE Evidence Trials","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on PACIFIC-2 Phase III Trial of Imfinzi Concurrently Administered with Platinum-Based Chemoradiotherapy in Unresectable, Stage III Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi plus Chemotherapy Approved in China as First Immunotherapy Regimen for Patients with Locally Advanced or Metastatic Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zibotentan\/dapagliflozin combination Demonstrated Significant Albuminuria Reduction in Patients with Chronic Kidney Disease and Proteinuria in ZENITH-CKD Phase IIb Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Zibotentan","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZORA Real-World Evidence Demonstrates that Lokelma Substantially Increases Cardiorenal Patients\u2019 Chances of Maintaining Lifesaving RAASi Therapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Demonstrated Clinically Meaningful Survival Across Multiple HER2-expressing Advanced Solid Tumours in DESTINY-PanTumor02 Phase II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Improved Progression-Free Survival vs. Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Significantly Extended Progression-Free Survival vs. Chemotherapy in Patients with HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enhertu Approved in the EU as the first HER2-directed Therapy for Patients with HER2-mutant Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Plus Imfinzi Demonstrated Robust and Durable Tumour Responses in 1st-line Treatment of Patients with Metastatic Triple-negative Breast Cancer in BEGONIA Phase Ib\/II trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi plus Lynparza Reduced the Risk of Disease Progression or Death by 45% vs. Chemotherapy in Advanced or Recurrent Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Plus Chemotherapy Reduced the Risk of Disease Progression in the Brain by 42% in Patients with EGFR-mutated Advanced Lung Cancer and Brain Metastases at Baseline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Icosavax","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-A12","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wainua (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Eplontersen Sodium","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ's Newest PNH med Voydeya Approved in Japan","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eplontersen granted U.S. FDA Fast Track Designation for Patients with Transthyretin-mediated Amyloid Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Eplontersen Sodium","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAGRISSO\u00ae (osimertinib) with the Addition of Chemotherapy Approved in the US for Patients with EGFR-mutated Advanced Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR-Positive, HER2-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Plus Chemotherapy More than Doubled Pathologic Complete Response Rate in Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers versus Chemotherapy Alone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-positive, HER2-negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Datopotamab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VOYDEYA\u2122 Approved in the US as Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Significantly Improved Overall Survival and Progression-Free Survival for Patients with Limited-Stage Small Cell Lung Cancer in ADRIATIC Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) Approved in the US as First Tumor-Agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FASENRA Approved for Treatment of Children Aged 6 to 11 with Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Benralizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae (durvalumab) plus Chemotherapy Doubled Overall Survival Rate at Three Years for Patients with Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voydeya Approved in the EU as Add-on Treatment to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH who have Residual Haemolytic Anaemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Danicopan","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BioCity Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCity Announces the First Patient Dosed with its Anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib\/II Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"BC3402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Truqap Plus Faslodex Recommended for Approval in the EU by CHMP for Patients with Advanced ER-positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Combination Regimen Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in 1st-line Mantle Cell Lymphoma in ECHO Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Acerta Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acerta Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Compugen","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"$10.0 million","newsHeadline":"Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Rilvegostomig","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.20999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"Acquisition of Fusion Pharmaceuticals Completed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Ac225-PSMA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":2.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":2.3999999999999999,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BenevolentAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI Announces Further Success with AstraZeneca Collaboration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga approved in the US for the treatment of paediatric type-2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BenevolentAI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BenevolentAI and AstraZeneca Collaboration Yields Further Novel Target Progress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sipavibart Meets Primary Endpoints In Phase III COVID-19 Prevention Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Sipavibart","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"SixPeaks Bio AG Debuts With $110 Million in Funding","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0.080000000000000002,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi approved in the US for endometrial cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae Shows Survival Benefit in Limited-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI\u00ae Shows Significant Improvement in Survival for Bladder Cancer in NIAGARA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU\u00ae Shows 13.2-Month PFS in HER2-Low Metastatic Breast Cancer After Endocrine Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trastuzumab Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE Plus Chemoimmunotherapy Reduces Progression Risk in Lymphoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Acerta Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Acerta Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CAPItello-290 Phase III: Truqap Plus Chemo in Advanced Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Capivasertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Granted Priority Review for Unresectable Stage III Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAGRISSO\u00ae Reduces Disease Progression Risk by 84% in Stage III EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amolyt Pharma","pharmaFlowCategory":"D","amount":"$1,050.0 million","upfrontCash":"$800.0 million","newsHeadline":"AstraZeneca Closes Acquisition of Amolyt Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Eneboparatide","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":1.05,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Pinetree Therapeutics","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$45.0 million","newsHeadline":"Pinetree Announces Option and Global License Agreement with AstraZeneca for EGFR Degrader","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0.5,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ AstraZeneca","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Imfinzi Fails in Late-Stage Trial to Treat Certain Lung Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Conduit Pharmaceuticals Signs Exclusive License with AstraZeneca for Novel Treatments","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2024","year":"2024","type":"Licensing Agreement","leadProduct":"AZD1656","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Conduit Pharma","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Approves AstraZeneca\u2019s Tagrisso with Chemotherapy for EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CALQUENCE\u00ae Plus Venetoclax Improves Survival in 1st-line CLL in AMPLIFY Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"AstraZenec.."}]

    Find Clinical Drug Pipeline Developments & Deals by AstraZeneca

    Menu

    AstraZeneca

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Farxiga approved in the US for the treatment of paediatric type-2 diabetes

                            Details : Farxiga (dapagliflozin), is first-in-class, oral, USFDA approved, once-daily SGLT2 inhibitor, for paediatric patients with type-2 diabetes aged 10 years and older.

                            Product Name : Farxiga

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2024

                            Lead Product(s) : Dapagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ac225-PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Fusion Pharma

                            Deal Size : $2,400.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Acquisition of Fusion Pharmaceuticals Completed

                            Details : Through the acquisition, AstraZeneca will leverage the Fusion pipeline, which includes FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer.

                            Product Name : FPI-2265

                            Product Type : Small molecule

                            Upfront Cash : $2,000.0 million

                            June 04, 2024

                            Lead Product(s) : Ac225-PSMA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Fusion Pharma

                            Deal Size : $2,400.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Daiichi Sankyo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ENHERTU® Shows 13.2-Month PFS in HER2-Low Metastatic Breast Cancer After Endocrine Therapy

                            Details : Enhertu (trastuzumab deruxtecan) is a HER2-directed ADC which is being evaluated for the treatment of previously treated patients with HR positive, HER2 low metastatic breast cancer.

                            Product Name : Enhertu

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2024

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Daiichi Sankyo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Compugen

                            Deal Size : $210.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 T...

                            Details : AZD2936 (rilvegostomig) is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902.

                            Product Name : AZD2936

                            Product Type : Large molecule

                            Upfront Cash : $10.0 million

                            May 30, 2024

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Compugen

                            Deal Size : $210.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monoclonal Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Nona Biosciences

                            Deal Size : $604.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Ant...

                            Details : Under the agreement, AstraZeneca will have the exclusive global license for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 22, 2024

                            Lead Product(s) : Monoclonal Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Nona Biosciences

                            Deal Size : $604.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Daiichi Sankyo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progress...

                            Details : Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate which is being evaluated in phase 3 clinical trials for the treatment of previously treated patients with HR positive, HER2 low ...

                            Product Name : Enhertu

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 29, 2024

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Daiichi Sankyo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Durvalumab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            IMFINZI® (durvalumab) plus Chemotherapy Doubled Overall Survival Rate at Three Years for Patients...

                            Details : Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is being evaluated for the treatment of patients...

                            Product Name : Imfinzi

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 16, 2024

                            Lead Product(s) : Durvalumab,Cisplatin,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nirsevimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Beyfortus Approved in Japan for the Prevention of RSV Disease in Infants

                            Details : Beyfortus (nirsevimab) is a single dose long-acting antibody, which is approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and in...

                            Product Name : Beyfortus

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 27, 2024

                            Lead Product(s) : Nirsevimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Sanofi

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capivasertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Dia...

                            Details : Truqap (capivasertib) is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3), is approved in combination with Faslodex (fulvestrant) for the t...

                            Product Name : Truqap

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 27, 2024

                            Lead Product(s) : Capivasertib,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Chugai Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Boulder Peptide 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Osimertinib Mesylate,Pemetrexed,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tagrisso with the Addition of Chemotherapy Showed Favourable Trend in Overall Survival in EGFR-mut...

                            Details : Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.

                            Product Name : Tagrisso

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2024

                            Lead Product(s) : Osimertinib Mesylate,Pemetrexed,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth